Darrin M. Beaupre, MD, head of Early Development and Immunotherapy at Pharmacyclics, discusses a trial of ibrutinib (Imbruvica) in diffuse large B-cell lymphoma (DLBCL).
Darrin M. Beaupre, MD
Advertisement
Articles by Darrin M. Beaupre, MD
Darrin M. Beaupre, MD, head of Early Development and Immunotherapy at Pharmacyclics, discusses a trial exploring the efficacy of ibrutinib in patients with marginal zone lymphoma.
Advertisement
Latest Updated Articles
Dr. Beaupre on Ibrutinib in Marginal Zone LymphomaPublished: February 2nd 2017 | Updated:
Dr. Beaupre on Ibrutinib in Diffuse Large B-Cell LymphomaPublished: March 30th 2017 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
The OncFive: Top Oncology Articles for the Week of 1/25
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5